Fulcrum Therapeutics is a clinical-stage biopharmaceutical company, founded in 2016, with a mission to enhance the quality of life for patients suffering from genetically defined diseases in areas of high unmet medical need, initially focusing on rare diseases. Specializing in the Biotechnology and Health Care industries, the company is headquartered in the United States. Notably, it received a substantial $125.00MPost-IPO Equity investment on 17 January 2023. The company remains dedicated to making a difference in the healthcare sector and is well-positioned to bring about advancements in treating rare and genetically defined diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $125.00M | - | 17 Jan 2023 | |
| Post-IPO Equity | $75.00M | - | 15 Aug 2022 | |
| Post-IPO Equity | $144.20M | - | 10 Aug 2021 | |
| Post-IPO Equity | $50.60M | - | 19 Jan 2021 | |
| Post-IPO Equity | $68.50M | 8 |
|
09 Jun 2020 |
No recent news or press coverage available for Fulcrum Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
